Spineway 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Stephane Le Roux

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	6yrs
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

Recent updates

CEO

Stephane Le Roux

no data

테뉴어

€121,331

보상

Mr. Stephane Le Roux serves as the Chairman, CEO and President of Spineway Société Anonyme.

리더십 팀

이름	위치	테뉴어	보상	소유권
Stephane Le Roux	Chairman	no data	€121.33k	데이터 없음
Philippe Laurito	Director & CTO of Spineway Inc.	6yrs	€121.33k	데이터 없음
David Siegrist	Financial Director	no data	데이터 없음	데이터 없음
Agnès Mignani	Human Resources Manager	no data	데이터 없음	데이터 없음
Sandrine Carle	Deputy Chief Executive Officer	less than a year	데이터 없음	데이터 없음
Guillaume Bertet	Controller	no data	데이터 없음	데이터 없음
Mickaël Battisti	Controller	no data	데이터 없음	데이터 없음
Marie-Christelle Desmolles	Controller	no data	데이터 없음	데이터 없음
Jon Luedke	CEO of Spineway Inc.	6yrs	데이터 없음	데이터 없음

6.0yrs

평균 재임 기간

경험이 풍부한 관리: 37S0 의 관리팀은 노련하고 경험 (평균 재직 기간 6 년)입니다.

Spineway 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Less than half of directors are independent

Spineway SA, Annual General Meeting, Mar 25, 2024

Spineway SA, Annual General Meeting, Mar 25, 2024

Spineway Sa Announces the Appointment of Sandrine Carle as Deputy Chief Executive Officer

Less than half of directors are independent

Recent updates

New minor risk - Financial data availability

Less than half of directors are independent

Spineway SA to Report First Half, 2024 Results on Sep 24, 2024

Less than half of directors are independent

Spineway SA, Annual General Meeting, Mar 25, 2024

Full year 2023 earnings released

Spineway SA, Annual General Meeting, Mar 25, 2024

Spineway SA to Report Q4, 2023 Results on Feb 07, 2024

Spineway Sa Announces the Appointment of Sandrine Carle as Deputy Chief Executive Officer

Spineway Group Obtains 510(K) Clearance from the US Food and Drug Administration for its VEOS Spinal Fixation System

First half 2023 earnings released

New minor risk - Financial data availability

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

New major risk - Financial position

Less than half of directors are independent

Spineway SA to Report First Half, 2023 Results on Sep 19, 2023

Spineway SA to Report Fiscal Year 2022 Results on Feb 09, 2023

Less than half of directors are independent

First half 2022 earnings released

Spineway SA (ENXTPA:ALSPW) agreed to acquire Spine Innovations SAS from LBO France.

Spineway SA, Annual General Meeting, May 18, 2022

Less than half of directors are independent

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Spineway Société Anonyme, Annual General Meeting, Mar 23, 2022

Spineway Société Anonyme (ENXTPA:ALSPW) signed a memorandum of understanding to acquire Distimp.

Spineway in Negotiations to Acquire European Spinal Surgery Start-Up

Spineway Société Anonyme Announces Signature of A Partnership with Tsunami Medical

Spineway Société Anonyme, Annual General Meeting, Mar 08, 2021

Full year 2020 earnings released: €0.005 loss per share (vs €0.064 loss in FY 2019)

Spineway Société Anonyme to Report First Half, 2021 Results on Sep 03, 2021

CEO

테뉴어

보상

리더십 팀

평균 재임 기간